Sei Investments Co. Grows Stock Holdings in Qiagen (NYSE:QGEN)

Sei Investments Co. grew its holdings in Qiagen (NYSE:QGEN) by 19.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,696,319 shares of the company’s stock after acquiring an additional 278,930 shares during the period. Sei Investments Co. owned about 0.74% of Qiagen worth $69,702,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its position in Qiagen by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock valued at $382,856,000 after purchasing an additional 83,371 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of Qiagen by 0.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock valued at $151,526,000 after buying an additional 26,078 shares during the period. Optiver Holding B.V. lifted its position in Qiagen by 1,211.4% during the 4th quarter. Optiver Holding B.V. now owns 47,212 shares of the company’s stock worth $2,050,000 after acquiring an additional 43,612 shares in the last quarter. US Bancorp DE boosted its holdings in Qiagen by 124.4% in the 1st quarter. US Bancorp DE now owns 75,529 shares of the company’s stock worth $3,247,000 after acquiring an additional 41,868 shares during the period. Finally, Parkman Healthcare Partners LLC acquired a new stake in Qiagen in the fourth quarter valued at approximately $10,858,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of QGEN stock opened at $44.90 on Friday. The stock has a market capitalization of $10.25 billion, a price-to-earnings ratio of 30.11, a PEG ratio of 3.32 and a beta of 0.39. Qiagen has a one year low of $34.74 and a one year high of $47.44. The company’s 50-day simple moving average is $44.93 and its 200-day simple moving average is $43.48. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The company had revenue of $496.00 million for the quarter, compared to the consensus estimate of $495.45 million. During the same quarter last year, the business posted $0.53 EPS. Qiagen’s quarterly revenue was down .2% compared to the same quarter last year. Equities analysts anticipate that Qiagen will post 2.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Robert W. Baird boosted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Finally, Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Qiagen currently has a consensus rating of “Moderate Buy” and an average target price of $51.10.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.